New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
04:55 EDTBIOD, BIOD, BIOD, BIOD, BIOD, LXRX, LXRX, LXRX, LXRX, LXRX, ISIS, ISIS, ISIS, ISIS, ISIS, LLY, LLY, LLY, LLY, LLYAmerican Diabetes Association to hold scientific sessions
74th Scientific Sessions of the ADA to be held in San Francisco on June 13-17.
News For BIOD;LXRX;ISIS;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 17, 2014
10:51 EDTLLYOptions with increasing implied volatility
Options with increasing implied volatility: COV DISH HLT QEP GREK BKW BYI LLY DTV TIBX
October 16, 2014
14:36 EDTLLYLilly to close Guayama facility, will take 16c charge in Q4
Eli Lilly announced plans to conclude production and pursue a sale of one of its three manufacturing plants in Puerto Rico. The manufacturing site, located in Guayama, Puerto Rico, will remain in operation until the end of 2015. All of the approximately 100 full-time non-contracted employees currently working in Guayama will be offered employment at Lilly's Carolina, Puerto Rico, location. As a result of this action, the company expects to record a charge of approximately $170M or approximately 16c per share, after tax, in Q414. While Lilly will initiate efforts to sell the Guayama site, the company will continue to invest in two manufacturing plants at Carolina. In November 2013, Lilly announced a $200M investment to increase capacity in its Carolina-based insulin active ingredient manufacturing plant. In July, Lilly announced an additional $40M in investments to increase capabilities at its Carolina-based drug product site as part of a rebalancing of Lilly's oral solid dosage network.
October 15, 2014
09:57 EDTISISLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
October 14, 2014
07:15 EDTLLYBiotech Industry Organization to hold a summit
Subscribe for More Information
October 13, 2014
07:12 EDTISISOligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
October 10, 2014
10:03 EDTLLYEli Lilly olaratumab granted orphan designation as soft tissue sarcoma treatment
Subscribe for More Information
09:00 EDTISISOn The Fly: Pre-market Movers
Subscribe for More Information
05:22 EDTISISIsis Pharmaceuticals reports data from ISIS-SMN Rx Phase 2 study
Subscribe for More Information
October 9, 2014
07:02 EDTISISIsis Pharmaceuticals receives $18M milestone payment from GlaxoSmithKline
Subscribe for More Information
October 8, 2014
11:10 EDTISISOptions with increasing implied volatility
Subscribe for More Information
10:55 EDTLLYLeerink pharmaceuticals analyst holds an analyst/industry conference call
Analysts discuss prospects for drugs that raise HDL cholesterol, effects of CETP mechanism, expectations for REVEAL data and the potential place for CETP inhibitors in a crowded hypersholesterolemia landscape on an Analyst/Industry conference call to be held on October 9 at 11 am.
06:11 EDTLLYNovartis says expects three executive committee members to leave
Novartis (NVS) confirmed that following completion of the transactions with GlaxoSmithKline (GSK) and Eli Lilly and Company (LLY) in the coming months, that the three business leaders of the Novartis divisions at the center of the transaction will leave the Executive Committee of Novartis. The expected changes to the ECN are subject to the closing of the transactions announced on April 22 - Novartis expects the transaction with GSK to be completed in the first half of 2015, and the transaction with Eli Lilly for its Animal Health Business to close in the first quarter of 2015. George Gunn, currently Division Head, Novartis Animal Health, will reach his contractual retirement age in July 2015 and will retire from Novartis. Upon closing of the Animal Health transaction with Lilly he will leave the ECN. Brian McNamara, currently Division Head, Novartis OTC, will transition to GSK as Head of Americas and Europe for the consumer health businesses, reporting to the President of GSK Consumer Healthcare, effective at closing of the transaction. Andrin Oswald, currently Division Head, Novartis Vaccines, will be leaving Novartis to pursue other opportunities following closing of the transaction with GSK.
October 7, 2014
10:56 EDTISISOptions with increasing implied volatility
Subscribe for More Information
October 6, 2014
14:24 EDTISISIsis Pharmaceuticals volatility elevated into update on Phase 2 clinical studies
Isis Pharmaceuticals October weekly call option implied volatility is at 120, October is at 94, November is at 73, January is at 64; compared to its 26-week average of 65 according to Track Data, suggesting large price movement into management providing an update on the Phase 2 clinical studies of ISIS-SMN Rx results presented at the 19th International World Muscle Society Congress on October 10.
07:13 EDTISISMobile Marketing & Technology Magazine to hold a conference
Mobile Payments Conference is being held in Chicago on October 6-8.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use